H

Hainan Poly Pharm Co Ltd
SZSE:300630

Watchlist Manager
Hainan Poly Pharm Co Ltd
SZSE:300630
Watchlist
Price: 0.89 CNY Market Closed
Market Cap: ¥68.4m

Relative Value

There is not enough data to reliably calculate the relative value of Hainan Poly Pharm Co Ltd.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
Not Available
H
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Hainan Poly Pharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Hainan Poly Pharm Co Ltd
SZSE:300630
68.4m CNY 0 -5.5 1 989.9 1 989.9
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.3 55.9 37.5 40.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
525.7B USD 5.6 19.6 13.7 16.8
CH
Roche Holding AG
SIX:ROG
277.8B CHF 4.5 29.4 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 4.9 30.4 19.8 28.9
CH
Novartis AG
SIX:NOVN
221.9B CHF 5 19.5 15.7 20.2
US
Merck & Co Inc
NYSE:MRK
271.6B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.7 17.4 12 14
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
148.4B USD 2.4 15.1 7.6 10.4
P/E Multiple
Earnings Growth PEG
CN
H
Hainan Poly Pharm Co Ltd
SZSE:300630
Average P/E: 25.2
Negative Multiple: -5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.9
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.4
37%
0.8
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
17.4
3%
5.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
H
Hainan Poly Pharm Co Ltd
SZSE:300630
Average EV/EBITDA: 573.6
1 989.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.5
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.7
-1%
N/A
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.8
10%
2
CH
Novartis AG
SIX:NOVN
15.7
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
12
1%
12
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
H
Hainan Poly Pharm Co Ltd
SZSE:300630
Average EV/EBIT: 1 883.1
1 989.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.8
4%
4.2
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.9
23%
1.3
CH
Novartis AG
SIX:NOVN
20.2
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
14
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5